[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 35, Issue 4 (winter 2025) ::
MEDICAL SCIENCES 2025, 35(4): 406-411 Back to browse issues page
Investigating dimethyl fumarate derivatives as drugs against oxidative stress using the molecular docking with KEAP1 protein
Saeedreza Emamian1 , Javad Hosseini2 , Safa Ali-Asgari2
1- Associate Professor, Department of Chemistry and Biochemistry, Shahrood Branch, Islamic Azad University, Shahrood, Iran , saeedreza_em@yahoo.com
2- Assistant Professor, Department of Chemistry and Biochemistry, Shahrood Branch, Islamic Azad University, Shahrood, Iran
Abstract:   (4 Views)
Abstract
Background: Oxidative stress is the starting point of many chronic diseases, including diabetes, cancer, and the cause of Alzheimer's, Parkinson's, and multiple sclerosis. KEAP1-NRF2 pathway is the principal protective response to oxidative and electrophilic stresses. The presence of KEAP1-NRF2 system in multiple cellular and metabolic message pathways suggests NRF2 activation as a critical regulatory factor in many disease phenotypes. In this research, the molecular docking of DMF and its three derivatives DMNBF, DMCBF and DMBBF with Keap1 protein to activate NRF2 with the aim of dealing with oxidative and electrophilic stresses was investigated.
Materials and methods: The affinity energy value for DMF and its three derivatives, DMNBF, DMCBF and DMBBF, with Keap1 protein in the three active regions of the protein was calculated using the molecular docking method and the type of interactions was determined.
Results: The results showed that DMNBF binds to Keap1 protein with affinity energy of 5.9, 5.7 and 3.7 kcal in all three active regions more effectively than DMF and other derivatives.
Conclusion: DMF is an approved drug for the treatment of psoriasis and multiple sclerosis. It interacts with Keap1 to activation of NRF2 in order to protective response against oxidative stress. Similarly, the DMNBF molecule may be able to be studied in lower doses and with fewer side effects for the treatment of psoriasis and multiple sclerosis or for the activation of NRF2 in the treatment of diseases that are somehow related to the KEAP1-NRF2 system
Keywords: Molecular docking, Oxidative stress, Reactive oxygen species, KEAP1-NRF2 pathway, Dimethyl fumarate derivatives
Full-Text [PDF 1379 kb]   (2 Downloads)    
Semi-pilot: Basic | Subject: Molecular Biology
Received: 2024/11/19 | Accepted: 2025/01/21 | Published: 2025/12/1
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Emamian S, Hosseini J, Ali-Asgari S. Investigating dimethyl fumarate derivatives as drugs against oxidative stress using the molecular docking with KEAP1 protein. MEDICAL SCIENCES 2025; 35 (4) :406-411
URL: http://tmuj.iautmu.ac.ir/article-1-2321-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 35, Issue 4 (winter 2025) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4732